PureTech Health plc Share Price
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126.00 GBX | +1.45% |
|
+5.53% | +0.80% |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| 07-13 | PureTech Health: Celea Therapeutics Kicks Off Late-stage Trial for Idiopathic Pulmonary Fibrosis Drug | MT |
| Market Cap | 413M 361M 334M 307M 580M 39.84B 591M 3.99B 1.57B 19.46B 1.55B 1.52B 67.17B | P/E 2026 * |
-3.72x | P/E 2027 * | -4.44x |
|---|---|---|---|---|---|
| Enterprise Value | 145M 126M 117M 107M 203M 13.93B 206M 1.39B 547M 6.8B 543M 531M 23.48B | EV / Sales 2026 * |
20.4x | EV / Sales 2027 * | 12.6x |
| Free-Float |
84.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PureTech Health plc
| 1 day | +1.45% | ||
| 1 week | +5.53% | ||
| Current month | -8.30% | ||
| 1 month | -2.78% | ||
| 3 months | -4.26% | ||
| 6 months | -7.35% | ||
| Current year | +0.80% |
| 1 week | 119.2 |  | 127 |
| 1 month | 115 | | 140.02 |
| Current year | 107.4 | | 143.6 |
| 1 year | 104.71 | | 148 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 410.66 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 14/07/2025 |
Eric Elenko
PSD | President | 53 | 08/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 31/07/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 07/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 31/12/2008 |
| Director/Board Member | 73 | 30/09/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 13/03/26 | Buy | Founder | 112,509 | 0.0466% | ||
| 24/09/25 | Buy | Chairman | 65,250 | 0.0272% | ||
| 24/09/25 | Buy | Director | 59,100 | 0.0246% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.45% | +5.53% | -8.03% | -41.67% | 408M | |
| -1.07% | -1.27% | +0.95% | +5.66% | 50.35B | |
| -2.85% | -6.25% | +366.61% | +572.09% | 39.21B | |
| +1.98% | +4.82% | +13.71% | +61.68% | 34.6B | |
| +1.78% | +0.73% | +32.68% | -4.80% | 34.52B | |
| +0.06% | +1.56% | +4.41% | +27.42% | 27.05B | |
| -3.27% | -5.67% | - | - | 16.68B | |
| +1.64% | +0.45% | +70.86% | +121.18% | 15.11B | |
| +0.29% | +1.02% | +14.95% | +17.80% | 13.85B | |
| -1.21% | +0.73% | +18.02% | -30.96% | 13.18B | |
| Average | -0.12% | +0.66% | +57.13% | +80.93% | 24.5B | |
| Weighted average by Cap. | -0.31% | +0.42% | +77.35% | +118.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.1M 6.21M 5.74M 5.27M 9.97M 684M 10.14M 68.45M 26.89M 334M 26.66M 26.08M 1.15B | 13.47M 11.77M 10.89M 9.99M 18.91M 1.3B 19.23M 130M 51M 634M 50.57M 49.46M 2.19B |
| Net income | -124M -108M -100M -92.05M -174M -11.96B -177M -1.2B -470M -5.84B -466M -456M -20.16B | -96.8M -84.61M -78.25M -71.8M -136M -9.33B -138M -933M -367M -4.55B -364M -356M -15.73B |
| Net Debt | -269M -235M -217M -199M -378M -25.91B -384M -2.59B -1.02B -12.65B -1.01B -988M -43.69B | -244M -214M -198M -181M -343M -23.55B -349M -2.36B -925M -11.5B -918M -898M -39.7B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/26 | GBX 126.00 | +1.45% | 379,718 |
| 15/07/26 | GBX 124.20 | -1.11% | 291,074 |
| 14/07/26 | GBX 125.60 | +1.95% | 295,785 |
| 13/07/26 | GBX 123.20 | +2.67% | 458,039 |
| 10/07/26 | GBX 120.00 | +0.50% | 296,103 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition